Skip to Main content Skip to Navigation
Journal articles

A porcine model of phenylketonuria generated by CRISPR/Cas9 genome editing

Abstract : Phenylalanine hydroxylase-deficient (PAH-deficient) phenylketonuria (PKU) results in systemic hyperphenylalaninemia, leading to neurotoxicity with severe developmental disabilities. Dietary phenylalanine (Phe) restriction prevents the most deleterious effects of hyperphenylalaninemia, but adherence to diet is poor in adult and adolescent patients, resulting in characteristic neurobehavioral phenotypes. Thus, an urgent need exists for new treatments. Additionally, rodent models of PKU do not adequately reflect neurocognitive phenotypes, and thus there is a need for improved animal models. To this end, we have developed PAH-null pigs. After selection of optimal CRISPR/Cas9 genome-editing reagents by using an in vitro cell model, zygote injection of 2 sgRNAs and Cas9 mRNA demonstrated deletions in preimplantation embryos, with embryo transfer to a surrogate leading to 2 founder animals. One pig was heterozygous for a PAH exon 6 deletion allele, while the other was compound heterozygous for deletions of exon 6 and of exons 6-7. The affected pig exhibited hyperphenylalaninemia (2000-5000 mu M) that was treatable by dietary Phe restriction, consistent with classical PKU, along with juvenile growth retardation, hypopigmentation, ventriculomegaly, and decreased brain gray matter volume. In conclusion, we have established a large-animal preclinical model of PKU to investigate pathophysiology and to assess new therapeutic interventions.
Document type :
Journal articles
Complete list of metadata

https://hal.inrae.fr/hal-03158896
Contributor : Martine Bouissou-Matet <>
Submitted on : Thursday, March 4, 2021 - 10:52:57 AM
Last modification on : Friday, September 10, 2021 - 2:51:39 PM

Links full text

Identifiers

Collections

Citation

Erik Koppes, Bethany Redel, Marie Johnson, Kristen Skvorak, Lina Ghaloul-Gonzalez, et al.. A porcine model of phenylketonuria generated by CRISPR/Cas9 genome editing. JCI Insight, American Society for Clinical Investigation, 2020, 5 (20), ⟨10.1172/jci.insight.141523⟩. ⟨hal-03158896⟩

Share

Metrics

Record views

26